IDBI Healthcare Growth Direct Plan
SIP amount
Temporarily restricted by fund house
Lumpsum amount
Temporarily restricted by fund house

IDBI Healthcare Growth Direct Plan

NAV
₹32.4172
-1.59%
(20 Dec)
AUM
84 Cr
TER
1.21%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+48.6%
+36.5%
+35.4%
+34.5%
+23.3%
3Y
+20.2%
+38.6%
+36.8%
+36.3%
+36.3%
5Y
+24.9%
+25.7%
+28.8%
+31.2%
NA
ALL
+22.4%
+12.3%
+17.5%
+17.9%
+28.0%
VOL
15.9%
20.3%
19.6%
18.1%
22.7%
TER
1.2%
0.7%
0.8%
1.2%
0.5%
AUM
₹84 Cr
₹4,686 Cr
₹1,345 Cr
₹6,779 Cr
₹5,456 Cr
INFO
1.42
0.61
0.89
0.99
1.24
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
IDBI Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Oct
Top holdings
Sun Pharmaceuticals Industries Ltd
10.1%
Piramal Pharma Ltd
7.5%
Artemis Medicare Services Ltd Ordinary Shares
5.9%
Torrent Pharmaceuticals Ltd
4.9%
Glenmark Pharmaceuticals Ltd
4.9%
J.B. Chemicals & Pharmaceuticals Ltd
4.7%
Mankind Pharma Ltd
4.7%
Cipla Ltd
4.4%
Suven Pharmaceuticals Ltd
4.3%
Ipca Laboratories Ltd
4.2%
Top industry exposure
Healthcare
90.2%
Basic Materials
2.8%
Other information
Minimum SIP
Restricted (AMC)
Minimum lumpsum
Restricted (AMC)
Additional lumpsum
Restricted (AMC)
Portfolio turnover
38%
Lock-in period
-
Exit load
• 1% for redemption within 90 days
Fund objective
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. However there can be no assurance that the investment objective under the scheme will be realized.
Fund manager(s)
Karan Doshi

FAQs